China’s pharmaceutical industry holds a competitive edge due to its large domestic market, substantial R&D investments, advanced manufacturing capabilities for the basic pharmaceutical building blocks, and robust government support. For India to enhance its competitiveness, it must boost R&D investments, reduce API dependency, and improve its regulatory environment. China continues to solidify its position in innovative drug products by way of strategic alliances with large MNCs. Indian Pharma needs to take urgent steps in order to close the gap and remain relevant on the global stage.
How Indian Pharma Manufacturers can Close the Gap with China